IN2012DN05169A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN05169A IN2012DN05169A IN5169DEN2012A IN2012DN05169A IN 2012DN05169 A IN2012DN05169 A IN 2012DN05169A IN 5169DEN2012 A IN5169DEN2012 A IN 5169DEN2012A IN 2012DN05169 A IN2012DN05169 A IN 2012DN05169A
- Authority
- IN
- India
- Prior art keywords
- serum half
- glycovariant
- introducing
- increasing
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26609509P | 2009-12-02 | 2009-12-02 | |
| US32758210P | 2010-04-23 | 2010-04-23 | |
| PCT/US2010/058765 WO2011068993A1 (fr) | 2009-12-02 | 2010-12-02 | Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN05169A true IN2012DN05169A (fr) | 2015-10-23 |
Family
ID=44115295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5169DEN2012 IN2012DN05169A (fr) | 2009-12-02 | 2010-12-02 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8722615B2 (fr) |
| EP (1) | EP2507267B1 (fr) |
| JP (1) | JP2013512674A (fr) |
| KR (1) | KR20140015152A (fr) |
| CN (1) | CN102770458A (fr) |
| AU (1) | AU2010325943A1 (fr) |
| BR (1) | BR112012013330A2 (fr) |
| CA (1) | CA2782320A1 (fr) |
| IN (1) | IN2012DN05169A (fr) |
| RU (1) | RU2012127383A (fr) |
| WO (1) | WO2011068993A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| EP2507267B1 (fr) | 2009-12-02 | 2016-09-14 | Acceleron Pharma, Inc. | Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc |
| US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
| US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| AU2013291982B2 (en) * | 2012-07-18 | 2017-01-12 | Apogenix Ag | Shortened CD95-Fc variants |
| WO2014130659A1 (fr) | 2013-02-22 | 2014-08-28 | New York University | Protéines chimères du facteur de croissance des fibroblastes 23 et méthodes d'utilisation |
| EP2969009B1 (fr) * | 2013-03-15 | 2018-11-28 | Pyranose Biotherapeutics, Inc. | Protéines de fusion de fc modifiées |
| GB201316592D0 (en) * | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| SI3063275T1 (sl) | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
| CA2938066C (fr) * | 2014-02-02 | 2025-05-06 | Medimmune Limited | Protéine chimérique composée de domaine antagoniste de facteur de croissance nerveuse et domaine antagoniste de facteur de nécrose des tumeurs-a |
| CN106456714A (zh) * | 2014-03-28 | 2017-02-22 | 纽约大学 | Fgf23融合蛋白 |
| CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
| WO2016069889A1 (fr) | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Hybrides nucléase-transferrine à visée thérapeutique et procédés associés |
| CA2980757A1 (fr) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Proteines de fusion associees a la follistatine et leurs utilisations |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| WO2017023855A1 (fr) * | 2015-07-31 | 2017-02-09 | The General Hospital Corporation | Prothèses de protéine pour maladies ou affections mitochondriales |
| CA3004830A1 (fr) * | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition et methodes pour anticorps anti-tnfr2 |
| MA45554A (fr) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | Fusions de binucléase optimisées. |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| EP3848388B1 (fr) * | 2018-09-05 | 2025-08-20 | LG Chem, Ltd. | Polypeptide de fusion comprenant une région polypeptidique pouvant être o-glycosylée |
| CA3124352A1 (fr) | 2019-01-04 | 2020-07-09 | Resolve Therapeutics, Llc | Traitement de la maladie de sjogren a l'aide de proteines de fusion de type nucleases |
| US20230355722A1 (en) | 2020-06-29 | 2023-11-09 | Resolve Therapeutics, Llc | Treatment of sjogren’s syndrome with nuclease fusion proteins |
| KR102934708B1 (ko) | 2021-09-10 | 2026-03-05 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함한 발광 소자 |
| WO2025147696A1 (fr) | 2024-01-05 | 2025-07-10 | Resolve Therapeutics, Llc | Traitement de symptômes associés à une infection virale au sars-cov ou à une infection virale au sars-cov antérieure avec des agents nucléasiques |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US5945397A (en) | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| EP0611302B1 (fr) | 1991-10-15 | 2000-03-29 | MULLARKEY, Michael F. | Recepteurs pour le traitement des troubles inflammatoires de phase tardive |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| WO1995026985A1 (fr) | 1994-04-05 | 1995-10-12 | Board Of Regents, The University Of Texas System | Recepteurs modifies a signalisation continue |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| AU2363695A (en) | 1995-04-27 | 1996-11-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
| US7070783B1 (en) | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US5570401A (en) * | 1995-09-22 | 1996-10-29 | General Electric Company | BWR containment configuration having partitioned wetwell airspace |
| ATE247974T1 (de) | 1996-12-06 | 2003-09-15 | Amgen Inc | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
| WO1999011662A1 (fr) | 1997-09-05 | 1999-03-11 | Millennium Biotherapeutics, Inc. | Nouvelles molecules de la famille des proteines associees au ligand du tnfr et leurs utilisations |
| AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| CA2310575A1 (fr) | 1997-11-07 | 1999-05-20 | Uab Research Foundation | Procede d'augmentation de l'expression genique |
| US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| CA2321105A1 (fr) | 1998-02-17 | 1999-08-19 | Incyte Pharmaceuticals, Inc. | Proteine de la famille des recepteurs a chaine courte humains du tnf |
| BR9908226A (pt) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| DE69940808D1 (de) | 1998-03-04 | 2009-06-10 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (fr) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Variants d'anticorps et fragments de ceux-ci |
| WO1999053059A1 (fr) * | 1998-04-16 | 1999-10-21 | Genentech, Inc. | Secretion de proteines glycosylees au moyen d'une pro-sequence de l'activateur tissulaire du plasminogene |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| SE9803710L (sv) | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
| EP1123314B1 (fr) | 1998-10-20 | 2004-02-18 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Utilisation d'une souche de lactococcus produisant des cytokines pour traiter la colite |
| AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| AU2000236029A1 (en) | 1999-02-23 | 2000-09-14 | Anne Chew | Receptor isogenes: polymorphisms in the tissue necrosis factor receptor |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20030148955A1 (en) | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| EP1206265B1 (fr) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Composes inhibiteurs de la src kinase |
| AU6836200A (en) | 1999-08-10 | 2001-03-05 | Glaxo Group Limited | Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer |
| NZ529329A (en) | 1999-08-25 | 2005-06-24 | Immunex Corp | Compositions and methods for improved cell culture |
| GB9927681D0 (en) | 1999-11-23 | 2000-01-19 | Glaxo Group Ltd | Protein |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| EP1254227A2 (fr) | 2000-02-11 | 2002-11-06 | Amgen Inc. | Recepteur de la famille tnf |
| WO2001064889A2 (fr) | 2000-03-02 | 2001-09-07 | Xencor | CONCEPTION ET DECOUVERTE DE VARIANTS DU TNF-α A BASE DE PROTEINES DESTINES AU TRAITEMENT DES PATHOLOGIES LIEES AU TNF-$g(a) |
| AU4935701A (en) | 2000-03-24 | 2001-10-08 | Genentech Inc | Use of insulin for the treatment of cartilagenous disorders |
| US6800300B1 (en) | 2000-03-31 | 2004-10-05 | Vasogen Ireland Limited | Method for treating autoimmune and alloimmune diseases |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| ES2327102T3 (es) | 2000-09-05 | 2009-10-26 | Amgen Inc. | Moleculas analogas al receptor de tnf y usos de las mismas. |
| US6610750B1 (en) | 2000-09-15 | 2003-08-26 | Laboratoires Negma | Treatment of osteoarthritis |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US20020150582A1 (en) | 2001-02-08 | 2002-10-17 | Friedrichs Gregory S. | Method of treating or inhibiting cellular injury or cell death |
| EE200300408A (et) | 2001-02-23 | 2003-12-15 | Immunex Corporation | Aktiivsete valkude saagise suurendamine |
| US6972327B1 (en) | 2001-05-08 | 2005-12-06 | Immunex Corporation | Regeneration of chromatography material |
| KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| EP2292273A3 (fr) | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodelage et Glycoconjugaison de Peptides |
| MXPA04004166A (es) | 2001-11-07 | 2004-07-08 | Hoffmann La Roche | Aminopirimidinas y piridinas. |
| JP4363986B2 (ja) | 2001-12-21 | 2009-11-11 | イミュネックス・コーポレーション | タンパク質の精製方法 |
| US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2476934C (fr) | 2002-02-27 | 2009-06-16 | Immunex Corporation | Composition stabilisee du fragment fc et du recepteur tnf comprenant de l'arginine |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| ES2557741T3 (es) | 2002-03-27 | 2016-01-28 | Immunex Corporation | Procedimientos para incrementar la producción de polipéptidos |
| US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| US7067279B1 (en) | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
| US6974681B1 (en) | 2002-08-23 | 2005-12-13 | Immunex Corporation | Cell culture performance with vanadate |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| WO2004091499A2 (fr) | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Formation intracellulaire de conjugues de peptides |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| EP1636264A2 (fr) | 2003-06-24 | 2006-03-22 | MERCK PATENT GmbH | Molecules de recepteur du facteur de necrose tumorale a immunogenicite reduite |
| SG145712A1 (en) | 2003-08-01 | 2008-09-29 | Amgen Inc | Crystalline tumor necrosis factor receptor 2 polypeptides |
| WO2005014035A2 (fr) | 2003-08-08 | 2005-02-17 | Novo Nordisk Health Care Ag | Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique |
| US7268116B2 (en) | 2003-10-02 | 2007-09-11 | Genhunter Corp. | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
| KR20050082389A (ko) | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| AU2005257064B2 (en) | 2004-06-28 | 2012-05-10 | Yeda Research And Development Co. Ltd. | Chimeric proteins and uses thereof |
| US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| EP1844069A4 (fr) | 2005-01-28 | 2009-05-20 | Apollo Life Sciences Ltd | Molécules et leurs molécules chimériques |
| EP2305246B1 (fr) | 2005-01-31 | 2015-08-26 | The Trustees of the University of Pennsylvania | Inhibiteurs du facteur de nécrose tumorale |
| US8124732B2 (en) | 2005-06-24 | 2012-02-28 | Synageva Biopharma Corp. | Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken |
| EP2377554A1 (fr) | 2005-07-22 | 2011-10-19 | Amgen, Inc | Lyophilisés de protéine concentrés, procédés et utilisations |
| CN1954882A (zh) | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
| US7626895B2 (en) | 2005-12-01 | 2009-12-01 | International Business Machines Corporation | Removable media battery pack for powering a media accessor of an automated data-storage library |
| EP2089521A1 (fr) | 2006-02-08 | 2009-08-19 | Ercole Biotech, Inc. | Récepteurs de tnf solubles et leur utilisation pour le traitement de maladies |
| US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| IL182956A0 (en) | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
| EP2152751A1 (fr) | 2007-05-31 | 2010-02-17 | Genmab A/S | Protéines de fusion ou liéee à demi-vie étendue |
| EP2162535A4 (fr) | 2007-06-04 | 2011-02-23 | Novo Nordisk As | Glycosylation à liaisons o utilisant des n-acétylglucosaminyl transférases |
| US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| MX355042B (es) * | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) * | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| EP2507267B1 (fr) | 2009-12-02 | 2016-09-14 | Acceleron Pharma, Inc. | Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc |
| US8883982B2 (en) * | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
-
2010
- 2010-12-02 EP EP10835138.8A patent/EP2507267B1/fr active Active
- 2010-12-02 KR KR1020127017129A patent/KR20140015152A/ko not_active Withdrawn
- 2010-12-02 JP JP2012542194A patent/JP2013512674A/ja not_active Withdrawn
- 2010-12-02 RU RU2012127383/10A patent/RU2012127383A/ru not_active Application Discontinuation
- 2010-12-02 US US12/959,220 patent/US8722615B2/en not_active Expired - Fee Related
- 2010-12-02 BR BR112012013330A patent/BR112012013330A2/pt not_active IP Right Cessation
- 2010-12-02 CN CN2010800629282A patent/CN102770458A/zh active Pending
- 2010-12-02 CA CA2782320A patent/CA2782320A1/fr not_active Abandoned
- 2010-12-02 IN IN5169DEN2012 patent/IN2012DN05169A/en unknown
- 2010-12-02 WO PCT/US2010/058765 patent/WO2011068993A1/fr not_active Ceased
- 2010-12-02 AU AU2010325943A patent/AU2010325943A1/en not_active Abandoned
-
2014
- 2014-04-24 US US14/261,212 patent/US20150010555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2507267B1 (fr) | 2016-09-14 |
| EP2507267A1 (fr) | 2012-10-10 |
| CN102770458A (zh) | 2012-11-07 |
| RU2012127383A (ru) | 2014-01-10 |
| JP2013512674A (ja) | 2013-04-18 |
| US8722615B2 (en) | 2014-05-13 |
| US20150010555A1 (en) | 2015-01-08 |
| BR112012013330A2 (pt) | 2017-03-28 |
| EP2507267A4 (fr) | 2013-05-29 |
| KR20140015152A (ko) | 2014-02-06 |
| US20110171218A1 (en) | 2011-07-14 |
| AU2010325943A1 (en) | 2012-06-21 |
| CA2782320A1 (fr) | 2011-06-09 |
| WO2011068993A1 (fr) | 2011-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2507267A4 (fr) | Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc | |
| CY1118343T1 (el) | Αντισωματα συνδεσης twεακ | |
| EP4328304A3 (fr) | Demi-domaines de clivage modifiés | |
| WO2012142515A3 (fr) | Protéines hybrides fc comprenant de nouveaux lieurs ou agencements | |
| SG162687A1 (en) | Caustic stable chromatography ligands | |
| CA2705357C (fr) | Formulations pour proteines hybrides taci-immunoglobuline | |
| EA201171148A1 (ru) | Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7 | |
| MX389347B (es) | Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos. | |
| CU24058B1 (es) | Antagonistas de pcsk9 | |
| EP2333116A3 (fr) | Marqueurs de rejet de greffe de rein et de lésions rénales | |
| WO2012139134A3 (fr) | Procédés de modulation des protéines de fusion oncogènes | |
| WO2011047087A3 (fr) | Détection de protéine par l'intermédiaire de nanorapporteurs | |
| EP2516624A4 (fr) | Lignée cellulaire 3m | |
| MX2019003214A (es) | Formulaciones de proteina de inmunoglobulina del dominio variable dual estable. | |
| MX2009004167A (es) | Anticuerpos que enlazan epitopos cxcr7. | |
| WO2013075066A3 (fr) | Protéines ayant une demi-vie et d'autres propriétés améliorées | |
| TR201911082T4 (tr) | K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem. | |
| EP2808393A3 (fr) | Cellules de déficience fucosylation | |
| DK2135091T3 (da) | MS-fremgangsmåder til evaluering af glykaner | |
| IN2012DN02073A (fr) | ||
| AR113492A2 (es) | Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla | |
| BRPI1016204A2 (pt) | proteínas de fusão de anticorpos com sítios de ligação fcrn modificados | |
| BRPI0822044A2 (pt) | Combinação de uma proteina de fusão anti anticorpo para edb da fibronectina-il-2 e uma molécula de ligação a células b, progenitores de células b e/ou seu correspondente canceroso | |
| WO2012068317A3 (fr) | Procédés de production de protéines recombinantes | |
| CO6241120A2 (es) | (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS. |